Recomendaciones para el uso de everolimus en trasplante renal de novo: falsas creencias, mitos y realidades

Abstract

The immunosuppressive combination most commonly used in de novo kidney transplantation comprises a calcineurin inhibitor (CI), tacrolimus, a mycophenolic acid derivative and steroids. The evidence which underlies this practice is based in the Symphony trial with controlled follow-up of one year, in which no comparator group included the combination CI-mTOR inhibitor. Different high-quality clinical trials support the use of everolimus as a standard immunosuppressive drug associated with reduced exposure of a CI in kidney transplantation. This combination could improve health related outcomes in kidney transplantation recipients. The present recommendations constitute an attempt to summarise the scientific evidence supporting this practice, discuss false beliefs, myths and facts, and offer specific guidelines for safe use, avoiding complications.

Effectiveness of Maintenance Immunosuppression Therapies in a Matched-Pair Analysis Cohort of 16 Years of Renal Transplant in the Brazilian National Health System

“…These immunosuppressants are currently recommended as second treatment line in Brazil [11], which is reflected in their limited use in our study (3.0%). However, there is ongoing controversy regarding the effectiveness of these combinations [13,14,17,[42][43][44]. Some clinical trials [45] support the use of everolimus as a standard immunosuppressive drug leading to reduced exposure to CNI; however, this is not universal.…”